• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Philip Morris International Inc

    6/6/25 4:31:33 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    8-A12B 1 tm2517118d2_8a12b.htm FORM 8-A12B

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM 8-A

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES 

    PURSUANT TO SECTION 12(b) OR 12(g) OF THE 

    SECURITIES EXCHANGE ACT OF 1934

     

    Philip Morris International Inc. 

    (Exact Name of Registrant as Specified in Its Charter)

     

    Virginia   13-3435103
    (State of incorporation or organization)   (I.R.S. Employer Identification No.)
    677 Washington Blvd, Suite 1100
    Stamford, Connecticut
      06901
    (Address of Principal Executive Offices of Registrant)   (Zip Code)

     

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class
    to be so Registered
      Name of Each Exchange on Which
    Each Class is to be Registered
    2.750% Notes due 2029   New York Stock Exchange
    3.250% Notes due 2032   New York Stock Exchange

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. x

     

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

     

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

     

    Securities Act registration statement file number to which this form relates: 

    333-269690

     

    Securities to be registered pursuant to Section 12(g) of the Act: 

    None.

     

     

     

     

     

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 1. Description of Registrant’s Securities to be Registered.

     

    The descriptions of the general terms and provisions of the 2.750% Notes due 2029 and 3.250% Notes due 2032 of Philip Morris International Inc. (the “Registrant”), to be registered hereby, contained under the heading “Description of Debt Securities” in the Registrant’s Registration Statement on Form S-3 (No. 333-269690) (the “Registration Statement”) and under the heading “Description of Notes” in the Registrant’s Prospectus Supplement, dated June 3, 2025, to the Prospectus contained in the Registration Statement and filed pursuant to Rule 424(b) of the Securities Act of 1933, as amended, are incorporated by reference herein.

     

    Item 2. Exhibits.

     

    Exhibit   Description
       
    4.1   Form of 2.750% Global Note due 2029 (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed by the Registrant on June 6, 2025).
       
    4.2   Form of 3.250% Global Note due 2032 (incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed by the Registrant on June 6, 2025).
       
    4.3   Indenture, dated as of April 25, 2008, between the Registrant and HSBC Bank USA, National Association, as Trustee (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-3 (No. 333-150449), dated April 25, 2008).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

     

      PHILIP MORRIS INTERNATIONAL INC.
         
      By: /s/ DARLENE QUASHIE HENRY
      Name: Darlene Quashie Henry
      Title: Vice President, Associate General Counsel and Corporate Secretary

     

    DATE: June 6, 2025

     

     

     

    Get the next $PM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    11/16/2023$95.00Neutral
    Redburn Atlantic
    More analyst ratings

    $PM
    Financials

    Live finance-specific insights

    See more
    • Philip Morris International Participates in dbAccess Global Consumer Conference

      Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.01 to $7.14 and Adjusted Diluted EPS of $7.36 to $7.49, Representing Growth of 12% to 14%, 10.5% to 12.5% Excluding Currency Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at www.pmi.com/2025dbaccess and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for approximately one year. 2025 Full-Ye

      6/3/25 1:30:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Reports First-Quarter 2025 Results and Raises 2025 Full-Year Adjusted Diluted EPS Forecast for Currency Only

      Reported Diluted EPS Grew 24.6% to $1.72 Adjusted Diluted EPS Grew 12.7% to $1.69; and by 17.3% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 first-quarter results.1 "We achieved exceptionally strong performance in the first quarter, with continued volume growth supporting an excellent top-line performance and very strong margin expansion," said Jacek Olczak, Chief Executive Officer. "Our smoke-free business goes from strength to strength, delivering organic growth of over 20% in net revenues and over 33% in gross profit." "We remain confident in our ability to deliver superior results, despite an uncertain and volatile glob

      4/23/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Court Approves CCAA Plans to Resolve Tobacco Product-Related Claims and Litigation in Canada

      Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding has approved a plan of compromise and arrangement for RBH (the Plan). The Plan, as approved, will resolve all tobacco product-related claims and litigation in Canada against RBH and its affiliates, including PMI. The court also approved substantially similar plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM). As previously disclosed, RBH's court-appointed mediator and monitor filed a pr

      3/7/25 8:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Philip Morris International Participates in dbAccess Global Consumer Conference

      Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.01 to $7.14 and Adjusted Diluted EPS of $7.36 to $7.49, Representing Growth of 12% to 14%, 10.5% to 12.5% Excluding Currency Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at www.pmi.com/2025dbaccess and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for approximately one year. 2025 Full-Ye

      6/3/25 1:30:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International to Host Webcast of Presentation at the 2025 dbAccess Global Consumer Conference

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live webcast of the company's remarks and Q&A session with Emmanuel Babeau, Chief Financial Officer, at the 2025 dbAccess Global Consumer Conference on Tuesday, June 3, 2025, at approximately 11:15 a.m. CET (5:15 a.m. ET). The Webcast and presentation slides will be available at www.pmi.com/2025dbaccess, with a post-event recording of the webcast available for one year at the same site. The webcast will provide a live stream of the entire PMI session and can also be accessed on mobile devices by downloading PMI's free Investor Relations Mobile App at www.pmi.com/irapp. Philip Morris International: A Global S

      5/27/25 8:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Holds 2025 Virtual Annual Meeting of Shareholders

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) held its 2025 Annual Meeting of Shareholders today. André Calantzopoulos, Chairman of the Board, addressed shareholders and answered questions. Jacek Olczak, Chief Executive Officer, gave a business presentation, which included an overview of PMI's: excellent 2024 performance and impressive start to 2025; achievement of several key milestones in its smoke-free journey; positive results in the execution of its multicategory strategy; ability to deliver sustainable growth and returns in 2025 and beyond; steadfast commitment to shareholder returns. "Our smoke-free transformation continues to advance rapidly. We mark

      5/7/25 9:44:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Philip Morris International with a new price target

      Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

      5/22/25 8:27:06 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by UBS with a new price target

      UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

      4/25/25 8:25:28 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by Argus

      Argus upgraded Philip Morris International from Hold to Buy

      3/14/25 7:44:58 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    See more
    • Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

      Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

      9/17/24 9:11:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Names New External Affairs Leader

      Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

      3/26/24 5:48:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

      In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

      3/4/24 6:48:00 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:21:26 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:05:54 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      1/29/24 3:26:29 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:43 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:34 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Harker Victoria D was granted 1,002 shares, increasing direct ownership by 41% to 3,418 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:22 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    SEC Filings

    See more
    • SEC Form 8-A12B filed by Philip Morris International Inc

      8-A12B - Philip Morris International Inc. (0001413329) (Filer)

      6/6/25 4:31:33 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      6/6/25 4:06:34 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form FWP filed by Philip Morris International Inc

      FWP - Philip Morris International Inc. (0001413329) (Subject)

      6/3/25 4:06:20 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care